Advanced Bladder Cancer: Future Directions in Care
Closing out their panel on advanced bladder cancer management, key opinion leaders share their excitement for future evolutions within the treatment landscape.
Novel 2L Treatment Approaches in Advanced Bladder Cancer
Expert perspectives on novel treatment strategies in the second-line treatment setting of advanced bladder cancer.
Advanced Bladder Cancer: Informing Selection of 2L Therapy
Leaders in bladder cancer management consider factors that aid in their selection of second-line therapy.
Improving Care in Bladder Cancer: Palliative Radiation and Treatment Breaks
In light of individual patient needs, perspectives are shared on the roles of palliative radiation and treatment breaks in the setting of advanced bladder cancer.
Followup With Patients on Maintenance Therapy for Bladder Cancer
A brief discussion on optimal follow-up practices with patients on therapy for advanced bladder cancer.
Bladder Cancer: Treatment Options for Patients With a Partial Response
Following a patient with bladder cancer who had a partial response to frontline therapy, panelists consider the branching treatment pathway.
Bladder Cancer: Educating Patients on Treatment Schedules and Adverse Events
Genitourinary cancer experts share insight on best practices in educating patients on treatment schedules and adverse events when receiving therapy for advanced bladder cancer.
Bladder Cancer Management: Best Practices in Radiation Therapy
Focused discussion on the optimal use of radiation therapy strategies, alone or in combination with systemic therapy, for patients with advanced bladder cancer.
Role of Chemoradiation in Node-Positive Bladder Cancer
Key opinion leaders in bladder cancer consider the evolving role of chemoradiation in patients with node-positive disease.
Systemic Therapy for Cisplatin-Ineligible Patients With Bladder Cancer
Expert perspectives on first-line treatment options available to patients with advanced bladder cancer who are ineligible for cisplatin-based chemotherapy.
Factors in Selecting Frontline Therapy for Advanced Bladder Cancer
Centering focus on the first-line treatment armamentarium, key opinion leaders consider factors that aid in the selection of best therapy for patients with advanced bladder cancer.
Best Supportive Care for Patients With Bladder Cancer
A brief discussion on supportive care available to patients with bladder cancer and the role it plays within the treatment pathway.
Diagnosing Bladder Cancer: Best Practices in Workup and Staging
Shared insight on the standard work-up and staging practices used when a patient presents with newly diagnosed bladder cancer.
Patient Case Review: What is a Typical Presentation of Bladder Cancer?
Expert panelists review a patient presentation of bladder cancer and consider the typical signs and symptoms that may lead to a diagnosis.
The Future of Metastatic Urothelial Carcinoma Management
Closing out their review of metastatic urothelial carcinoma management, panelists share what they most look forward to in the evolving treatment landscape.
Optimizing Selection of ADC Therapy in Metastatic Urothelial Carcinoma
Focused discussion on the optimal selection and use of antibody-drug conjugate therapies in patients with metastatic urothelial carcinoma.
Sequencing Therapy Through Multiple Lines of Metastatic Urothelial Carcinoma
Expert perspectives on treatment sequencing pathways in metastatic urothelial carcinoma, with deference to recent trial data for both IO and ADC therapies.
Clinical Scenario 1: A 73-Year-Old Man With Metastatic Urothelial Carcinoma
The panel reviews a clinical scenario of metastatic urothelial carcinoma where the patient is not eligible for cisplatin treatment.
Metastatic Urothelial Carcinoma: Optimizing Maintenance Therapy After Chemo
A comprehensive review of maintenance therapy strategies following chemotherapy in the context of optimizing patient outcomes.
Clinical Scenario 1: A 63-Year-Old Woman With Metastatic Urothelial Carcinoma
Centering discussion on a clinical scenario of metastatic urothelial carcinoma, panelists determine which first-line regimen they would utilize prior to maintenance therapy.
Metastatic Urothelial Carcinoma Maintenance Therapy Data
A panel of experts reviews key clinical trial data supporting use of maintenance therapy in metastatic urothelial carcinoma.
Benefit of Maintenance Therapy in Metastatic Urothelial Carcinoma
Shared insight on the broader benefits of maintenance therapy in metastatic urothelial carcinoma and the mainstay agents in this setting.
Metastatic Urothelial Carcinoma: Overview of Treatment Options
Expert oncologists provide a comprehensive overview of treatment options available to patients with metastatic urothelial carcinoma.
Treatment Options for Localized Bladder Cancer
A brief review of both neoadjuvant and adjuvant treatment options available to patients with localized bladder cancer.
Overview on Urothelial Carcinoma: Risk Factors, Symptoms, and Staging
Opening their discussion on urothelial carcinoma management, panelists highlight risk factors, symptoms, and staging practices in this setting.
Emerging Data and Future Directions in UC
Experts highlight emerging data and novel regimens that have the biggest potential to impact treatment and management of patients with urothelial cancer.
ASCO GU 2022 Updates: PARP Inhibitors in First-Line and Subsequent UC Settings
Experts comment on the utility of PARP inhibitors in UC and discuss data presented at ASCO GU 2022.
ASCO GU 2022 Updates: Antibody-Drug Conjugates
Guru Sonpavde, MD, introduces emerging antibody-drug conjugates for treating metastatic UC, and reviews recent ASCO GU 2022 data on these regimens.
ASCO GU 2022 Updates: Trials on Combination Immunotherapy versus Chemotherapy
Petros Grivas, MD, PhD, transitions the panel discussion to focus on clinical trial data on combination immunotherapy versus platinum chemotherapy regimens that were recently presented at ASCO GU 2022.
Remaining Unmet Needs in Frontline Maintenance Therapy and Ongoing Trials for mUC
The panel summarizes unmet needs in frontline maintenance therapy for UC and comments on ongoing trials for novel treatment regimens.